The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years
Open accessAbstract
Introduction: Ankylosing spondylitis (AS) is a chronic rheumatic disease associated with spinal inflammation that subsequently leads to progression of structural damage and loss of function. The fully human anti-tumor necrosis factor (anti-TNF) antibody adalimumab reduces the signs and symptoms and improves overall quality of life in patients with active AS; these benefits have been maintained through 2 years of treatment. Our objective was to compare the progression of structural damage in the spine in patients with AS treated with adalimumab for up to 2 years versus patients who had not received TNF antagonist therapy. Methods: Radiographs from patients with AS who received adalimumab 40 mg every other week subcutaneously were pooled from the Adalimumab Trial Evaluating Long-Term Efficacy and Safety for Ankylosing Spondylitis (ATLAS) study and a Canadian AS study (M03-606). Radiographic progression from baseline to 2 years in the spine of adalimumab-treated patients from these two studies (adalimumab cohort, n = 307) was compared with an historic anti-TNF-naïve cohort (Outcome in AS International Study [OASIS], n = 169) using the modified Stoke AS Spine Score (mSASSS) method. Results: mSASSS results were not significantly different between the adalimumab cohort and the OASIS cohort, based on baseline and 2-year radiographs. Mean changes in mSASSS from baseline to 2 years were 0.9 for the OASIS cohort and 0.8 for the adalimumab cohort (P = 0.771), indicating similar radiographic progression in both groups. When results for patients in the OASIS cohort who met the baseline disease activity criteria for the ATLAS and Canadian studies (OASIS-Eligible cohort) were analyzed, there was no significant difference in mean change in mSASSS from baseline to 2 years between OASIS-Eligible patients and adalimumab-treated patients; the mean changes in mSASSS were 0.9 for the OASIS-Eligible cohort and 0.8 for the adalimumab cohort (P = 0.744). Conclusions: Two years of treatment with adalimumab did not slow radiographic progression in patients with AS, as assessed by the mSASSS scoring system, when compared with radiographic data from patients naïve to TNF antagonist therapy. Trial registration: Canadian study (M03-606) ClinicalTrials.gov identifier: NCT00195819; ATLAS study (M03-607) ClinicalTrials.gov identifier: NCT00085644.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evaluation of Diagnostic Criteria for Ankylosing Spondylitis
Linden, S. V. D., Valkenburg, H. A., & Cats, A. (1984) · Arthritis & Rheumatism · doi:10.1002/art.1780270401 · Cited by 5,697
Lam, J., Takeshita, S., Barker, J. E., Kanagawa, O., Ross, F. P., & Teitelbaum, S. L. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11176 · Cited by 1,440 · cited 1×
“In vitro and in vivo models indicate that the bone destruction is mediated by TNF activation of osteoclasts [12-14].”
BackgroundKeystone, E. C., Kavanaugh, A. F., Sharp, J. T., Tannenbaum, H., Hua, Y., Teoh, L. S., Fischkoff, S. A., & Chartash, E. K. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20217 · Cited by 1,172
Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors
Braun, J., Bollow, M., Remlinger, G., Eggens, U., Rudwaleit, M., Distler, A., & Sieper, J. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199801)41:1<58::aid-art8>3.0.co;2-g · Cited by 933
Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression
Mease, P. J., Kivitz, A. J., Burch, F. X., Siegel, E. L., Cohen, S. B., Ory, P., Salonen, D., Rubenstein, J., Sharp, J. T., & Tsuji, W. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20335 · Cited by 882
Self-citationvan der Heijde, D., Kivitz, A., Schiff, M. H., Sieper, J., Dijkmans, B. A. C., Braun, J., Dougados, M., Reveille, J. D., Wong, R. L., Kupper, H., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21913 · Cited by 872
Self-citationBraun, J., Bollow, M., Neure, L., Seipelt, E., Seyrekbasan, F., Herbst, H., Eggens, U., Distler, A., & Sieper, J. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380407 · Cited by 690
Ritchlin, C. T., Haas-Smith, S. A., Li, P., Hicks, D. G., & Schwarz, E. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16069 · Cited by 616
van der Heijde, D., Landewé, R., Einstein, S., Ory, P., Vosse, D., Ni, L., Lin, S. ‐., Tsuji, W., & Davis, J. C. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23471 · Cited by 549
Self-citationvan der Heijde, D., Klareskog, L., Rodriguez‐Valverde, V., Codreanu, C., Bolosiu, H., Melo‐Gomes, J., Tornero‐Molina, J., Wajdula, J., Pedersen, R., Fatenejad, S., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21655 · Cited by 535
Self-citationOsteoclasts are essential for TNF-α–mediated joint destruction
Redlich, K., Hayer, S., Ricci, R., David, J.-P., Tohidast-Akrad, M., Kollias, G., Steiner, G., Smolen, J. S., Wagner, E. F., & Schett, G. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15582 · Cited by 531
Heijde, D. V. D., Landewé, R., Baraliakos, X., Houben, H., Tubergen, A. V., Williamson, P., Xu, W., Baker, D., Goldstein, N., & Braun, J. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23901 · Cited by 514
Self-citationOsteoclasts are essential for TNF-α-mediated joint destruction.
Redlich, K., Hayer, S., Ricci, R., David, J.-P., Tohidast-Akrad, M., Kollias, G., Steiner, G., Smolen, J. S., Wagner, E. F., & Schett, G. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215582 · Cited by 474
Wanders, A. J. B., Landewé, R. B. M., Spoorenberg, A., Dougados, M., van der Linden, S., Mielants, H., van der Tempel, H., & van der Heijde, D. M. F. M. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20446 · Cited by 379
Self-citationThe relationship between inflammation and new bone formation in patients with ankylosing spondylitis
Baraliakos, X., Listing, J., Rudwaleit, M., Sieper, J., & Braun, J. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2496 · Cited by 240
van der Heijde, D., Schiff, M. H., Sieper, J., Kivitz, A. J., Wong, R. L., Kupper, H., Dijkmans, B. A. C., Mease, P. J., & Davis, J. C. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.087270 · Cited by 188
Self-citationEvidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis
Lories, R. J. U., Derese, I., de Bari, C., & Luyten, F. P. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22372 · Cited by 187
Baraliakos, X., Listing, J., Brandt, J., Haibel, H., Rudwaleit, M., Sieper, J., & Braun, J. (2007) · Rheumatology · doi:10.1093/rheumatology/kem166 · Cited by 178
Maksymowych, W. P., Landewé, R., Conner‐Spady, B., Dougados, M., Mielants, H., van der Tempel, H., Poole, A. R., Wang, N., & van der Heijde, D. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22589 · Cited by 164
Self-citationLories, R. J. U., Daans, M., Derese, I., Matthys, P., Kasran, A., Tylżanowski, P., Ceuppens, J. L., & Luyten, F. P. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21897 · Cited by 85
A longitudinal study on an autoimmune murine model of ankylosing spondylitis
Bárdos, T., Szabó, Z., Czipri, M., Vermes, C., Tunyogi-Csapó, M., Urban, R. M., Mikecz, K., & Glant, T. T. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.029710 · Cited by 72
Powell, A. J., Little, C. B., & Hughes, C. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22818 · Cited by 42
Cited by
IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells
Sherlock, J. P., Joyce-Shaikh, B., Turner, S. P., Chao, C.-C., Sathe, M., Grein, J., Gorman, D. M., Bowman, E. P., McClanahan, T. K., Yearley, J. H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2817 · Cited by 1,060
Dougados, M., & Baeten, D. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60071-8 · Cited by 780
Osteoimmunology: The conceptual framework unifying the immune and skeletal systems
Okamoto, K., Nakashima, T., Shinohara, M., Negishi-Koga, T., Komatsu, N., Terashima, A., Sawa, S., Nitta, T., & Takayanagi, H. (2017) · Physiological Reviews · doi:10.1152/physrev.00036.2016 · Cited by 534
Haroon, N., Inman, R. D., Learch, T. J., Weisman, M. H., Lee, M., Rahbar, M. H., Ward, M. M., Reveille, J. D., & Gensler, L. S. (2013) · Arthritis & Rheumatism · doi:10.1002/art.38070 · Cited by 490
Smolen, J. S., Braun, J., Dougados, M., Emery, P., FitzGerald, O., Helliwell, P., Kavanaugh, A., Kvien, T. K., Landewé, R., Luger, T., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203419 · Cited by 447
Self-citation
Metadata
- Authors
- van der Heijde, D., Salonen, D., Weissman, B. N., Landewé, R., Maksymowych, W. P., Kupper, H., Ballal, S., Gibson, E., Wong, R., & the Canadian (M03-606) study group and the ATLAS study group
- Venue
- Arthritis Research & Therapy
- Published
- 2009-08-24
- Volume
- 11
- Issue
- 4
- Pages
- R127-R127
- ISSN
- 1478-6354 (ISSN-L)
- OpenAlex
- W2143071958
- Cited by
- 413
- References
- 22
- FWCI
- 19.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.